OSE IMMUNOTHERAPEUTICS

Anti-chemokin like receptor 1 antibodies and their therapeutic applications

N° IL321209A

ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

N° US2025215108A1

LIPID-BASED NANOPARTICLES COMPRISING IL-35

N° WO2025133115A1

COMBINATION OF INTERLEUKIN 7 AND TUMOUR ASSOCIATED ANTIGEN VACCINE

N° WO2025093541A1

METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER

N° JP2025010617A

USE OF ANTI-SIRP-ALPHA ANTIBODIES TO TREAT CANCER

N° WO2025074328A1

USE OF ANTI-SIRP-ALPHA ANTIBODIES TO TREAT A LIVER DISEASE OR DISORDER

N° WO2025074337A1

METHODS FOR PROMOTING T CELLS RESPONSE

N° US2024400695A1

IDENTIFICATION OF HLA-DRA AS A LIGAND OF CLEC-1 AND USES THEREOF

N° WO2025032213A1

BIOMARKERS FOR ASSESSING THE RESPONSE STATUS FOR TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TRACT SUCH AS INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS

N° US2024384349A1

ANTI-CHEMOKIN LIKE RECEPTOR 1 ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

N° JP2024105648A

ANTI-CHEMOKIN LIKE RECEPTOR 1 ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

N° US2024400698A1

Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases

N° US2024294659A1

METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER

N° US2024279352A1

METHOD OF SYNTHESIS OF TARGETED LIPID NANOPARTICLE AND USES THEREOF

N° WO2024200820A1

LIPID-BASED NANOPARTICLE TARGETED AT ACTIVATED IMMUNE CELLS FOR THE EXPRESSION OF IMMUNE CELL ENHANCING MOLECULE AND USE THEREOF

N° WO2024200823A1

LIPID-BASED NANOPARTICLE TARGETED AT ACTIVATED IMMUNE CELLS FOR THE EXPRESSION OF IMMUNE CELL INHIBITING MOLECULE AND USE THEREOF

N° WO2024200826A1

ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127

N° US2024352135A1

ANTI-SIRP-ALPHA ANTIBODIES

N° JP2024056817A

Anticuerpos anti-sirp-alfa

N° CO2023017156A2

ANTICUERPOS ANTI-SIRP-alfa

N° CR20230573A

Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof

N° IL309107A

Anticuerpos anti-sirp-alfa

N° CL2023003554A1

ANTICUERPOS ANTI-SIRP-alfa

N° DOP2023000259A

Anti-sirp-alpha antibodies

N° IL308741A

Therapeutic predictive biomarkers for anti-SIRPa antibodies

N° CN120202222A

PREDICTIVE EFFICACY BIOMARKERS FOR ANTI-SIRPA ANTIBODIES

N° WO2024105180A1

New scaffold for bifunctional molecules with improved properties

N° IL307419A

Anti-CD28 Humanized Antibodies Formulated for Administration to Humans

N° US2025051446A1

ANTI-CHEMOKIN LIKE RECEPTOR 1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NETOSIS

N° WO2024028508A2

TREATMENT OF AN INFLAMMATION-ASSOCIATED DISEASE IN A PATIENT EXPRESSING HIGH CHEMERIN LEVEL

N° WO2024028509A2

Multifunctional molecules directed against CD28

N° CN119907811A

MULTIFUNCTIONAL MOLECULE DIRECTED AGAINST CD28

N° WO2024028386A1

MULTIFUNCTIONAL MOLECULE DIRECTED AGAINST CD28

N° EP4565610A1

HETERODIMERIC FC-CLEC-1 FUSION MOLECULE AND USES THEREOF

N° WO2024028347A1

HETERODIMERIC FC-CLEC-1 FUSION MOLECULE AND USES THEREOF

N° EP4565607A1

Heterodimeric Fc-CLEC-1 fusion molecules and uses thereof

N° CN119855827A

Bifunctional anti-pd1/il-7 molecules

N° IL303745A

BIOMARKERS OF IL7R MODULATOR ACTIVITY

N° WO2023232826A1

Biomarkers of IL7R modulator activity

N° CN119301276A

BIOMARKERS OF IL7R MODULATOR ACTIVITY

N° EP4499875A1

BIOMARKERS OF IL7R MODULATOR ACTIVITY

N° ES3023172T3

NEW CLASS OF MOLECULES FOR SELECTIVE CLEARANCE OF ANTIBODY

N° WO2023198806A1

Novel molecules for selective clearance of antibodies

N° CN119013290A

NEW CLASS OF MOLECULES FOR SELECTIVE CLEARANCE OF ANTIBODY

N° US2025250354A1

NEW CLASS OF MOLECULES FOR SELECTIVE CLEARANCE OF ANTIBODY

N° EP4508074A1

METHOD AND COMPOSITION FOR INDUCING DIFFERENTIATION OF MYELOID DERIVED SUPPRESSOR CELL TO TREAT CANCER AND INFECTIOUS DISEASES

N° JP2023078398A

Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

N° US2023227565A1

SPECIFIC ANTAGONIST ANTI-SIRPG ANTIBODIES

N° WO2023094698A1

Specific antagonist anti-SIRPG antibodies

N° CN118679183A

SPECIFIC ANTAGONIST ANTI-SIRPG ANTIBODIES

N° EP4441094A1

ANTI-SIRP-ALPHA ANTIBODIES

N° US2023203188A1

Identification of CLEC-1 ligands and uses thereof

N° CN118510534A

IDENTIFICATION OF CLEC-1 LIGAND AND USES THEREOF

N° WO2023083890A1

Identification of CLEC-1 Ligand and Uses Thereof

N° US2025026839A1

IDENTIFICATION OF CLEC-1 LIGAND AND USES THEREOF

N° EP4429692A1

CHIMERIC ANTIGEN RECEPTORS TARGETING CD127 AND USE THEREOF

N° US2023087125A1

Antibodies directed against CD127

N° US2023340133A1

Humanized anti-human-pd-1 antibody

N° IL296038A

Moléculas bifuncionales comprendiendo una variante de il-7

N° CO2022009700A2

PAN-CORONAVIRUS PEPTIDE VACCINE

N° WO2022268916A2

Bifunctional molecules comprising an il-7 variant

N° IL293745A

HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF

N° WO2022258714A1

인간화 항-CLEC-1A 항체 및 이의 항원 결합 단편 및 이의 모방체

N° KR20240019295A

HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF

N° EP4352097A1

HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF

N° US2024309096A1

Humanized anti-CLEC-1A antibodies and antigen binding fragments thereof and mimetics thereof

N° CN118139884A

HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF

N° CA3220346A1

HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF

N° AU2022290831A1

ANTI-SIRP-ALPHA ANTIBODIES

N° EP4347653A1

ANTI-SIRP-ALPHA ANTIBODIES

N° WO2022254379A1

Anti-SIRP-alpha antibodies

N° TW202317620A

ANTI-SIRP-ALPHA ANTIBODIES

N° CA3218692A1

Anticorpos anti-sirp-alfa

N° BR112023025194A2

ANTI-SIRP-ALPHA ANTIBODIES

N° PH12023553159A1

항-SIRP-알파 항체

N° KR20240027677A

Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment

N° US2022332826A1

ANTICUERPOS ANTI-SIRP-a

N° AR126067A1

Anti-SIRP-alpha antibodies

N° US2023012273A1

ANTI-SIRP-ALPHA ANTIBODIES

N° AU2022284373A1

METHOD FOR TREATING CD127-POSITIVE CANCERS BY ADMINISTERING AN ANTI-CD127 AGENT

N° WO2022248940A1

METHOD FOR TREATING CD127-POSITIVE CANCERS BY ADMINISTERING AN ANTI-CD127 AGENT

N° EP4347043A1

Methods of treating CD127 positive cancers by administering anti-CD127 agent

N° CN117769435A

Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases

N° US2022281993A1

METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER

N° US2022298259A1

ΜΕΘΟΔΟΣ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ ΕΝΟΣ ΣΤΑΘΕΡΟΥ ΓΑΛΑΚΤΩΜΑΤΟΣ ΓΙΑ ΤΗΝ ΧΟΡΗΓΗΣΗ ΠΕΠΤΙΔΙΩΝ

N° CY1125239T1

Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1)

N° US2022281983A1

Method for manufacturing a stable emulsion for peptide delivery

N° US2022259277A1

NEW SCAFFOLD FOR BIFUNCTIONAL MOLECULES WITH IMPROVED PROPERTIES.

N° MX2023011964A

SCAFFOLD FOR BIFUNCTIONAL MOLECULES COMPRISING PD-1 OR CD28 AND SIRP BINDING DOMAINS

N° US2024182572A1

SCAFFOLD FOR BIFUNCTIOANL MOLECULES COMPRISING PD-1 OR CD28 AND SIRP BINDING DOMAINS

N° EP4320156A1

NEW SCAFFOLD FOR BIFUNCTIONAL MOLECULES WITH IMPROVED PROPERTIES

N° CA3213917A1

NEW SCAFFOLD FOR BIFUNCTIONAL MOLECULES WITH IMPROVED PROPERTIES

N° US2024182571A1

Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapéuticas

N° CO2022004545A2

SCAFFOLD FOR BIFUNCTIOANL MOLECULES COMPRISING PD-1 OR CD28 AND SIRP BINDING DOMAINS

N° WO2022214652A1

특성이 향상된 이작용성 분자용 신규한 스캐폴드

N° KR20240005741A

NEW SCAFFOLD FOR BIFUNCTIONAL MOLECULES WITH IMPROVED PROPERTIES

N° WO2022214653A1

NEW SCAFFOLD FOR BIFUNCTIONAL MOLECULES WITH IMPROVED PROPERTIES

N° AU2022253351A1

NEW SCAFFOLD FOR BIFUNCTIONAL MOLECULES WITH IMPROVED PROPERTIES

N° EP4320155A1

Anti-chemokin like receptor 1 humanized antibodies and their therapeutic applications

N° IL292029A